Oncologic Drugs Advisory Committee Meeting June 2, 2006 Slides Presented at
Meeting Sprycel ™(Dasatib) NDA 21-986 |
|
Welcome and Introductory Comments |
Richard Pazdur,
M.D., Director Office of Oncology Drug Products, OODP |
Sponsor Presentation (ppt)
(htm) Introduction Problem Statement Clinical Program Clinical
Perspective & Benefit and Risk Assessment Conclusion |
Bristol-Myers Squibb Company Donna Morgan
Murray, Ph.D. Neil Shah, M.D., Claude Nicaise, M.D.,
VP, Global Development Hagop Kantarjian, M.D. MD Anderson Cancer Center Donna Morgan Murray, Ph.D. |
Efficacy Safety |
NDA 21-986 Edvardas
Kaminskas, M.D., DDOP, OODP Vicki Goodman,
M.D. DDOP, OODP |
Open Pulic Hearing |
|
|